Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Brief Communication
  • Published:

Reducing hydrophobicity of homogeneous antibody-drug conjugates improves pharmacokinetics and therapeutic index

Nature Biotechnology volume 33, pages 733–735 (2015)Cite this article

Subjects

Abstract

The in vitro potency of antibody-drug conjugates (ADCs) increases with the drug-to-antibody ratio (DAR); however, ADC plasma clearance also increases with DAR, reducing exposure and in vivo efficacy. Here we show that accelerated clearance arises from ADC hydrophobicity, which can be modulated through drug-linker design. We exemplify this using hydrophilic auristatin drug linkers and PEGylated ADCs that yield uniform, high-DAR ADCs with superior in vivo performance.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1: Structures of drug linkers and characterization of ADCs.
Figure 2: Structures of glucuronide-MMAE drug linkers and characterization of ADCs.

Similar content being viewed by others

References

  1. Sievers, E.L. & Senter, P.D. Annu. Rev. Med. 64, 15–29 (2013).

    Article  CAS  Google Scholar 

  2. Hamblett, K.J. et al. Clin. Cancer Res. 10, 7063–7070 (2004).

    Article  CAS  Google Scholar 

  3. Herbertson, R.A. et al. Clin. Cancer Res. 15, 6709–6715 (2009).

    Article  CAS  Google Scholar 

  4. Lyon, R.P., Meyer, D.L., Setter, J.R. & Senter, P.D. Methods Enzymol. 502, 123–138 (2012).

    Article  CAS  Google Scholar 

  5. Wang, L., Amphlett, G., Blattler, W.A., Lambert, J.M. & Zhang, W. Protein Sci. 14, 2436–2446 (2005).

    Article  CAS  Google Scholar 

  6. McDonagh, C.F. et al. Protein Eng. Des. Sel. 19, 299–307 (2006).

    Article  CAS  Google Scholar 

  7. Junutula, J.R. et al. Nat. Biotechnol. 26, 925–932 (2008).

    Article  CAS  Google Scholar 

  8. Jeffrey, S.C. et al. Bioconjug. Chem. 24, 1256–1263 (2013).

    Article  CAS  Google Scholar 

  9. Strop, P. et al. Chem. Biol. 20, 161–167 (2013).

    Article  CAS  Google Scholar 

  10. King, H.D. et al. J. Med. Chem. 45, 4336–4343 (2002).

    Article  CAS  Google Scholar 

  11. Miller, M.L. et al. J. Med. Chem. 47, 4802–4805 (2004).

    Article  CAS  Google Scholar 

  12. Moon, S.J. et al. J. Med. Chem. 51, 6916–6926 (2008).

    Article  CAS  Google Scholar 

  13. Zhao, R.Y. et al. J. Med. Chem. 54, 3606–3623 (2011).

    Article  CAS  Google Scholar 

  14. Jeffrey, S.C. et al. Bioconjug. Chem. 17, 831–840 (2006).

    Article  CAS  Google Scholar 

  15. Wahl, A.F. et al. Cancer Res. 62, 3736–3742 (2002).

    CAS  Google Scholar 

  16. Oflazoglu, E. et al. Clin. Cancer Res. 14, 6171–6180 (2008).

    Article  CAS  Google Scholar 

  17. Doronina, S.O. et al. Bioconjug. Chem. 17, 114–124 (2006).

    Article  CAS  Google Scholar 

Download references

Acknowledgements

We thank our Seattle Genetics colleagues S. Alley for assistance in pharmacokinetic modeling; J. Miyamoto for in vitro cytotoxicity assays; A. Cronkite for competition binding studies; and C. Zapata, C. Balasubramanian and W. Schultz for rat toxicology studies.

Author information

Authors and Affiliations

  1. Department of Chemistry, Seattle Genetics, Bothell, Washington, USA

    Robert P Lyon, Tim D Bovee, Svetlana O Doronina, Patrick J Burke, Joshua H Hunter, Jocelyn R Setter & Peter D Senter

  2. Department of Pharmacology and Toxicology, Seattle Genetics, Bothell,, Washington, USA

    Haley D Neff-LaFord

  3. Department of Translational Research, Seattle Genetics, Bothell, Washington, USA

    Mechthild Jonas

  4. Department of Preclinical Research, Seattle Genetics, Bothell, Washington, USA

    Martha E Anderson

Authors
  1. Robert P Lyon
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Tim D Bovee
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Svetlana O Doronina
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Patrick J Burke
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Joshua H Hunter
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Haley D Neff-LaFord
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Mechthild Jonas
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Martha E Anderson
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Jocelyn R Setter
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. Peter D Senter
    View author publications

    You can also search for this author in PubMed Google Scholar

Contributions

R.P.L. designed drug linkers, prepared and characterized ADCs by HIC, designed in vivo studies, performed the pharmacokinetic data fitting and wrote the manuscript; T.D.B. synthesized drug linkers; S.O.D. designed and synthesized drug linkers, P.J.B. designed and synthesized PEGylated drug linkers; J.H.H. performed radiolabeling and quantification for pharmacokinetic studies; H.D.N.-L. designed and interpreted the rat toxicology studies; M.J. performed IHC analysis of ADC uptake by rat liver; M.E.A. performed in vivo work (activity, pharmacokinetics and biodistribution); J.R.S. performed mass spectrometry assays to characterize ADC drug loading and stability, and to quantify MMAE delivery in vivo; P.D.S. directed the synthetic chemistry and co-wrote the manuscript.

Corresponding author

Correspondence to Robert P Lyon.

Ethics declarations

Competing interests

“All authors are employees of Seattle Genetics, Inc.”

Supplementary information

Supplementary Text and Figures

Supplementary Figures 1–9 and Supplementary Note (PDF 1171 kb)

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Lyon, R., Bovee, T., Doronina, S. et al. Reducing hydrophobicity of homogeneous antibody-drug conjugates improves pharmacokinetics and therapeutic index. Nat Biotechnol 33, 733–735 (2015). https://doi.org/10.1038/nbt.3212

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/nbt.3212

This article is cited by

Search

Advanced search

Quick links

Nature Briefing: Translational Research

Sign up for the Nature Briefing: Translational Research newsletter — top stories in biotechnology, drug discovery and pharma.

Get what matters in translational research, free to your inbox weekly. Sign up for Nature Briefing: Translational Research